GGrantIndex
Sort

15,440 grants matching organoids

Convergent Drivers of Tumor Evolution at the Mitotic Spindle

$560,290
Frank M Mason · Vanderbilt University Medical Center · R01 · FY2023 · CA

Production and progression of premalignant retinoblastoma lesions.

$560,197
David Cobrinik · Children'S Hospital Of Los Angeles · R01 · FY2025 · CA

Production and progression of premalignant retinoblastoma lesions.

$560,196
David Cobrinik · Children'S Hospital Of Los Angeles · R01 · FY2024 · CA

An organotypic model recapitulating colon cancer microenvironment and metastasis

$560,162
Emina Hui-Na Huang · Cleveland Clinic Lerner Com-Cwru · U01 · FY2017 · CA

Verteporfin as a YAP/TAZ inhibitor for treatment of glioblastoma

$560,145
Renee D Read · Emory University · R01 · FY2024 · NS

Tuft cell heterogeneity in function, lineage, and structure in ileal inflammatory disease

$560,104
Ken S Lau · Vanderbilt University · R01 · FY2024 · DK

Comparative analysis between patient-derived models of pancreatic ductal adenocarcinomas and matched tumor specimens

$560,027
Rosalie C Sears · Oregon Health & Science University · U01 · FY2020 · CA

Pancreatic Ductal Adenocarcinoma Translational Resource Center (PATReC)

$559,976
Anirban Maitra · University Of Tx Md Anderson Can Ctr · U24 · FY2021 · CA

Pancreatic Ductal Adenocarcinoma Translational Resource Center (PATReC)

$559,976
Anirban Maitra · University Of Tx Md Anderson Can Ctr · U24 · FY2020 · CA

Whole Genome Sequencing for Nephrotic Syndrome Discovery

$559,912
Matthew Gordon Sampson · Boston Children'S Hospital · R01 · FY2021 · DK

Development of iPSCs for comparative genomics in primates

$559,888
Yoav Gilad · University Of Chicago · R01 · FY2025 · HG

Development of iPSCs for comparative genomics in primates

$559,888
Yoav Gilad · University Of Chicago · R01 · FY2024 · HG

Translational Epigenetics with XIST: Silencing Trisomy in Human Organoid and Mouse Models of Down Syndrome

$559,872
Jeanne Bentley Lawrence · Univ Of Massachusetts Med Sch Worcester · R01 · FY2021 · HD

BRMS1-mediated suppression of metastases in p53 mutant lung adenocarcinoma

$559,847
David R Jones · Sloan-Kettering Inst Can Research · R01 · FY2020 · CA

BRMS1-mediated suppression of metastases in p53 mutant lung adenocarcinoma

$559,847
David R Jones · Sloan-Kettering Inst Can Research · R01 · FY2021 · CA

Synergistic combinatorial DNA damage response/repair inhibition and Sacituzumab Govitecan in triple-negative breast cancer

$559,783
Leif W Ellisen · Massachusetts General Hospital · R01 · FY2025 · CA

Synergistic combinatorial DNA damage response/repair inhibition and Sacituzumab Govitecan in triple-negative breast cancer

$559,783
Leif W Ellisen · Massachusetts General Hospital · R01 · FY2022 · CA

Refining iPSC-Based Spinal Cord Model Systems by Fabricating Developmentally Programmed Extracellular Matrix Cues

$559,496
Evangelos Kiskinis · Northwestern University At Chicago · R01 · FY2024 · AG

Integrative and longitudinal multi-omic risk assessment in inflammatory bowel disease progression

$559,348
Subra Kugathasan · Emory University · U01 · FY2025 · DK

Transcriptional Regulation of Lung Alveolar Regeneration

$559,288
Edward E Morrisey · University Of Pennsylvania · R01 · FY2024 · HL

The role of PKM2 in dietary lipid absorption and fructose-induced obesity

$559,196
Marcus Dasilva Goncalves · Weill Medical Coll Of Cornell Univ · R01 · FY2023 · DK

Mechanisms of alteration of gastrointestinal physiology by gut microbes

$559,098
Purna C Kashyap · Mayo Clinic Rochester · R01 · FY2024 · DK

Pharmacogenomic and circulating tumor cell approach to individualized treatment of pancreatic cancer

$558,719
Kenneth H. Yu · Sloan-Kettering Inst Can Research · R01 · FY2019 · CA

A conserved transcriptional cascade involved in brain overgrowth, social behavior and autism

$558,715
Anthony J Wynshaw-Boris · Case Western Reserve University · R01 · FY2017 · MH

Type I IFN signaling during lung development in Down Syndrome

$558,694
Soula Athanasia Danopoulos · Lundquist Institute For Biomedical Innovation At Harbor-Ucla Medical Center · R01 · FY2025 · HL